文献速递消化、代谢与肾脏急症心脑血管急症

度拉糖肽与2型糖尿病心血管结局(REWIND):双盲、随机、安慰剂对照试验

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
PubMed 文献 · Lancet · 2019-06-09
一句话结论在2型糖尿病合并心血管疾病或心血管危险因素的中老年患者中,每周皮下注射度拉糖肽1.5 mg可降低主要不良心血管事件(HR 0.88,95%CI 0.79-0.99;p=0.026)。

REWIND是一项在24个国家371个中心开展的多中心、随机、双盲、安慰剂对照试验,纳入9901例年龄≥50岁、有既往心血管事件或心血管危险因素的2型糖尿病患者,随机接受每周皮下注射度拉糖肽1.5 mg或安慰剂。中位随访5.4年,主要复合终点(非致死性心肌梗死、非致死性卒中或心血管原因死亡)在度拉糖肽组发生率为2.4/100人年(594例,12.0%),安慰剂组为2.7/100人年(663例,13.4%),HR 0.88(95%CI 0.79-0.99;p=0.026)。全因死亡率两组无显著差异(HR 0.90,95%CI 0.80-1.01;p=0.067)。度拉糖肽组胃肠道不良事件发生率高于安慰剂组(47.4% vs 34.1%;p<0.0001)。作者认为,对于合并心血管疾病或心血管危险因素的中老年2型糖尿病患者,可考虑使用度拉糖肽进行血糖管理。

要点

  • 纳入年龄≥50岁、有既往心血管事件或心血管危险因素的2型糖尿病患者,随机接受每周皮下注射度拉糖肽1.5 mg或安慰剂。
  • 主要复合终点(非致死性心肌梗死、非致死性卒中或心血管原因死亡)度拉糖肽组12.0%(2.4/100人年)vs 安慰剂组13.4%(2.7/100人年),HR 0.88(95%CI 0.79-0.99;p=0.026)。
  • 全因死亡率度拉糖肽组10.8% vs 安慰剂组12.0%,HR 0.90(95%CI 0.80-1.01;p=0.067),两组无显著差异。
  • 胃肠道不良事件度拉糖肽组47.4% vs 安慰剂组34.1%(p<0.0001)。
  • 作者认为,对于合并心血管疾病或心血管危险因素的中老年2型糖尿病患者,可考虑使用度拉糖肽进行血糖管理。

适用人群与场景

  • 年龄至少50岁、患有2型糖尿病,且有既往心血管事件或心血管危险因素的男性和女性。

处置流程与药物剂量

  • 度拉糖肽1.5 mg,每周一次皮下注射,作为现有降糖方案的附加治疗。

研究设计与关键结果

  • 多中心、随机、双盲、安慰剂对照试验,在24个国家371个中心开展,纳入9901例参与者(平均年龄66.2岁[SD 6.5],中位HbA1c 7.2%[IQR 6.6-8.1],女性4589例[46.3%]),随机分配至度拉糖肽组(n=4949)或安慰剂组(n=4952)。
  • 中位随访5.4年(IQR 5.1-5.9),主要复合终点(非致死性心肌梗死、非致死性卒中或心血管原因死亡)在度拉糖肽组发生594例(12.0%),发生率2.4/100人年;安慰剂组发生663例(13.4%),发生率2.7/100人年;HR 0.88(95%CI 0.79-0.99;p=0.026)。
  • 全因死亡率度拉糖肽组536例(10.8%)vs 安慰剂组592例(12.0%),HR 0.90(95%CI 0.80-1.01;p=0.067)。
  • 胃肠道不良事件度拉糖肽组2347例(47.4%)vs 安慰剂组1687例(34.1%)(p<0.0001)。

证据类型、等级与局限

  • 证据类型:多中心、随机、双盲、安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对于合并心血管疾病或心血管危险因素的中老年2型糖尿病患者,可考虑使用度拉糖肽进行血糖管理。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c (HbA1c) concentrations. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse cardiovascular events when added to the existing antihyperglycaemic regimens of individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of glycaemic control.

METHODS: This multicentre, randomised, double-blind, placebo-controlled trial was done at 371 sites in 24 countries. Men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors were randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (1·5 mg) or placebo. Randomisation was done by a computer-generated random code with stratification by site. All investigators and participants were masked to treatment assignment. Participants were followed up at least every 6 months for incident cardiovascular and other serious clinical outcomes. The primary outcome was the first occurrence of the composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes (including unknown causes), which was assessed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01394952.

FINDINGS: Between Aug 18, 2011, and Aug 14, 2013, 9901 participants (mean age 66·2 years [SD 6·5], median HbA1c 7·2% [IQR 6·6-8·1], 4589 [46·3%] women) were enrolled and randomly assigned to receive dulaglutide (n=4949) or placebo (n=4952). During a median follow-up of 5·4 years (IQR 5·1-5·9), the primary composite outcome occurred in 594 (12·0%) participants at an incidence rate of 2·4 per 100 person-years in the dulaglutide group and in 663 (13·4%) participants at an incidence rate of 2·7 per 100 person-years in the placebo group (hazard ratio [HR] 0·88, 95% CI 0·79-0·99; p=0·026). All-cause mortality did not differ between groups (536 [10·8%] in the dulaglutide group vs 592 [12·0%] in the placebo group; HR 0·90, 95% CI 0·80-1·01; p=0·067). 2347 (47·4%) participants assigned to dulaglutide reported a gastrointestinal adverse event during follow-up compared with 1687 (34·1%) participants assigned to placebo (p<0·0001).

INTERPRETATION: Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.

FUNDING: Eli Lilly and Company.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. PMID: 31189511. doi:10.1016/S0140-6736(19)31149-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。